Influenza Virus Vaccine Efficacy Based On Conserved Sequence Alignment

TL;DR

This paper reviews the challenges in influenza vaccine efficacy, emphasizing the importance of conserved sequence alignment for developing more effective vaccines and highlighting experimental approaches to improve vaccine success.

Contribution

It introduces a simple experimental method using conserved sequence alignment to evaluate and enhance influenza vaccine efficacy.

Findings

Identifies deficiencies in current vaccine efficacy research.

Proposes a conserved sequence alignment approach for vaccine evaluation.

Highlights the need for standardized vaccination strategies.

Abstract

The rapid outbreak of bird flu challenges the outcome of effective vaccine for the upcoming years. The recent research established different norms to eliminate flu pandemics. This can be made possible with skilled experimental analyses and by tracking the recent virulent strain and can be broadly applicable with effective testing of vaccine efficacy. Every year World Health Organization (WHO) reveals the administration of drug and vaccine to counter arrest the spread of flu among the population. As there are recurrent failures in priming the population, the complete eradication of the flu pandemic is still appears to be an unresolved problem. To overcome the current scenario, high level efforts with theoretical and practical research is required and it can enhance the scope in this field. The recent advancements also allow the researchers to endeavor effective vaccine to meet the emerging flu types. Only the standardized vaccination among the population at the time of flu pandemics will revolutionalize the current propositions against influenza virus. This paper shows the deficiencies of vaccine fitness research as there are reported failures and less efficacy of vaccine even after priming the population from referred evidences and studies. It also shows simple experimental approach in detecting the effective vaccine among the vaccines announced by WHO.